GLYCOMIMETICS INC
For the period ended Dec 31, 2023. Filed Mar 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 27, 2024
CBIO$14.76+6.0%Stored close · as of Nov 11, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Operations and Comprehensive Loss
Checking your notes…
| | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| · · Year Ended December 31, · | ||||||||||
| · · 2023 · · 2022 · · 2021 | ||||||||||
| | | | | | | | | | | |
| Revenue from collaboration and license agreements | | $10,000 | | $75,000 | | $1,159,767 | | |||
| | | | | | | | | | | |
| Costs and expenses: | | | | | | | | | | |
| Research and development expense | | 20,071,656 | | 28,390,879 | | 47,491,567 | | |||
| General and administrative expense | | 19,213,637 | | 19,087,443 | | 17,115,405 | | |||
| Total costs and expenses | | 39,285,293 | | 47,478,322 | | 64,606,972 | | |||
| Loss from operations | | (39,275,293) | | (47,403,322) | | (63,447,205) | | |||
| Interest income | | 2,375,873 | | 714,520 | | 19,768 | | |||
| Net loss and comprehensive loss | | $(36,899,420) | | $(46,688,802) | | $(63,427,437) | | |||
| Basic and diluted net loss per common share | | $(0.58) | | $(0.89) | | $(1.23) | | |||
| Basic and diluted weighted-average number of common shares outstanding | | 63,342,465 | | 52,531,173 | | 51,453,204 | | |||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.